ストックスクリーナーアプリを入手
12.04
3.99%
-0.50
前日終値:
$12.54
開ける：
$12.725
24時間の取引高:
3.95M
Relative Volume:
2.98
時価総額：
$1.34B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-8.60
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
-24.84%
1か月 パフォーマンス:
-30.51%
6か月 パフォーマンス:
-54.27%
1年 パフォーマンス:
-35.44%
1日の値動き範囲:
$11.57
$12.73
1週間の範囲:
$11.57
$16.61
52週間の値動き範囲:
$11.57
$34.13
Novocure Ltd Stock (NVCR) Company Profile
NVCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.04 | 1.40B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
NovoCure: Q2 Earnings Snapshot - Greenwich Time
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Novocure Ltd. Reports Q2 2025 Financial Results - TipRanks
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
How NovoCure Limited stock performs during market volatilityTargeted 200 Percent Gain - Newser
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
NovoCure Ltd (NVCR) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Novocure stock hits 52-week low at 14.17 USD - Investing.com Australia
Novocure Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Novocure: Steady Ahead of Key Milestones - The Motley Fool
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
NovoCure Ltd Q2 2025 Earnings: EPS Loss of $0.36 Beats Estimates - GuruFocus
Novocure Ltd earnings beat by $0.02, revenue topped estimates - Investing.com South Africa
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure Reports Second Quarter 2025 Financial Results - Stock Titan
What analysts say about NovoCure Limited stockBreakthrough wealth creation - Autocar Professional
What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com
Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser
Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser
NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st
Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest
LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World
NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria
New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan
Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World
Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
大文字化:
|
ボリューム (24 時間):